Prognostic evaluation in multiple myeloma:: an analysis of the impact of new prognostic factors

被引:0
|
作者
Turesson, I [1 ]
Abildgaard, N
Ahlgren, T
Dahl, IM
Holmberg, E
Hjorth, M
Nielsen, JL
Odén, A
Seidel, C
Waage, A
Westin, J
Wislöff, F
机构
[1] Malmo Univ Hosp, Dept Med, S-20502 Malmo, Sweden
[2] Aarhus Univ Hosp, Dept Med & Haematol, DK-8000 Aarhus, Denmark
[3] Univ Tromso Hosp, Dept Med, N-9038 Tromso, Norway
[4] Sahlgrens Univ Hosp, Ctr Oncol, S-41345 Gothenburg, Sweden
[5] Lidkoping Hosp, Dept Med, Lidkoping, Sweden
[6] Norwegian Univ Sci & Technol, Inst Canc Res & Mol Biol, N-7034 Trondheim, Norway
[7] Univ Trondheim Hosp, Dept Med, N-7006 Trondheim, Norway
[8] Univ Lund Hosp, Dept Med, S-22185 Lund, Sweden
[9] Ullevaal Univ Hosp, Dept Med, Oslo, Norway
关键词
multiple myeloma; survival; prognostic factors; risk score;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We have analysed the prognostic information for survival of presenting features in an unselected series of 394 myeloma patients. 15 variables with significant prognostic information were identified, among these were some not previously or only recently reported: serum levels of hepatocyte growth factor (HGF), interleukin-6 (IL-6), C-terminal crosslinked telopeptide of collagen I (ICTP) and soluble interleulrin-6 receptor (siL-6R). In a multivariate Cox analysis six variables were significantly and independently associated with poor survival: high age, low W.H.O.-performance status (PS), high serum levels of calcium, beta-2-microglobulin (beta-2M), IL-6 and sIL-6R, A risk score formed to predict survival for each percentile of the patient population allowed an efficient separation of prognostic groups. The discriminating power of the model compared favourably with three other previously published staging systems applied to the study population, Exclusion of IL-6 and sIL-6R from the model only marginally decreased the efficacy of the separation. The predictive value of some variables (sIL-6R, beta-2M and W.H.O.-PS) decreased significantly over time. We conclude that formation of a risk score based on independent variables is an efficient way to separate prognostic groups, that the contribution of new and not easily available parameters should be thoroughly evaluated before inclusion in prognostic models for clinical use and that the predictive value of parameters may decrease over time.
引用
收藏
页码:1005 / 1012
页数:8
相关论文
共 50 条
  • [31] Prognostic impact of the complete response in multiple myeloma
    Gay, Julie
    Leleu, Xavier
    HEMATOLOGIE, 2009, 15 (06): : 412 - 413
  • [32] IS THERE A PROGNOSTIC IMPACT OF THE CEREBLON EXPRESSION IN MULTIPLE MYELOMA?
    Bila, J.
    Sretenovic, A.
    Jelicic, J.
    Tosic, N.
    Glumac, I.
    Fekete, M. Dencic
    Antic, D.
    Balint, M. Todorovic
    Markovic, O.
    Puric, M.
    Milojevic, Z.
    Radojkovic, M.
    Trajkovic, G.
    Pavlovic, S.
    Mihaljevic, B.
    HAEMATOLOGICA, 2016, 101 : 259 - 260
  • [33] PROGNOSTIC FACTORS IN MULTIPLE-MYELOMA - CRITICAL ANALYSIS IN 84 PATIENTS
    BENITEZ, O
    DEGRAMONT, A
    HUBERT, D
    SIRINELLI, A
    BRISSAUD, P
    SMADJA, N
    KRULIK, M
    DEBRAY, J
    SEMAINE DES HOPITAUX, 1984, 60 (40): : 2791 - 2794
  • [34] The prognostic impact of inflammatory factors in patients with multiple myeloma treated with thalidomide in Korea
    Kim, Cheolsu
    Lee, Ho Sup
    Min, Chang-Ki
    Lee, Je Jung
    Kim, Kihyun
    Yoon, Dok Hyun
    Eom, Hyeon Seok
    Lee, Hyewon
    Lee, Won Sik
    Shin, Ho-Jin
    Lee, Ji Hyun
    Park, Yong
    Jo, Jae-Cheol
    Do, Young Rok
    Mun, Yeung-Chul
    KOREAN JOURNAL OF INTERNAL MEDICINE, 2015, 30 (05): : 675 - 683
  • [35] PROGNOSTIC FACTORS OF MULTIPLE-MYELOMA - MULTIVARIATE LIFE-TABLE ANALYSIS OF MULTIPLE-MYELOMA
    WATANABE, E
    YANO, K
    HUKUTANI, H
    TAKEYAMA, H
    KATO, R
    YOKOMAKU, S
    KAMIYA, O
    NAGATA, K
    OHARA, K
    YASUMA, A
    SHIMIZU, S
    KATO, Y
    NISHIWAKI, H
    MIZUNO, H
    OHTA, H
    SHIMIZU, K
    KAWASHIMA, K
    NAGURA, E
    MITOMO, Y
    YOSHIKAWA, S
    YOSHIKAWA, H
    HIRABAYASHI, N
    ESAKI, K
    KOBAYASHI, M
    IKEDA, Y
    TANAKA, M
    SHIBATA, T
    ACTA HAEMATOLOGICA JAPONICA, 1987, 50 (03): : 613 - 618
  • [36] Multiple myeloma in elderly patients: prognostic factors and outcome
    Anagnostopoulos, A
    Gika, D
    Symeonidis, A
    Zervas, K
    Pouli, A
    Repoussis, P
    Grigoraki, V
    Anagnostopoulos, N
    Economopoulos, T
    Maniatis, A
    Dimopoulos, MA
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2005, 75 (05) : 370 - 375
  • [37] Prognostic factors in multiple myeloma complicated with renal failure
    Chavynchak, R. B.
    Rekhtina, I. G.
    TERAPEVTICHESKII ARKHIV, 2008, 80 (01) : 84 - 88
  • [38] PROGNOSTIC FACTORS IN PATIENTS WITH BENCE JONES MULTIPLE MYELOMA
    De Veas Silva, J. L. Garcia
    Rios Tamayo, R.
    Bermudo Guitarte, C.
    Rojas Noboa, J. C.
    Duro Millan, R.
    De Haro Munoz, T.
    HAEMATOLOGICA, 2016, 101 : 798 - 798
  • [39] Prognostic:: factors for multiple myeloma in the era of novel agents
    Blade, J.
    Rosinol, L.
    Cibeira, M. T.
    ANNALS OF ONCOLOGY, 2008, 19 : 117 - 120
  • [40] LYMPHOID SUBSETS AND PROGNOSTIC FACTORS IN MULTIPLE-MYELOMA
    SANMIGUEL, JF
    GONZALEZ, M
    GASCON, A
    MORO, MJ
    HERNANDEZ, JM
    ORTEGA, F
    JIMENEZ, R
    GUERRAS, L
    ROMERO, M
    CASANOVA, F
    SANZ, MA
    SANCHEZ, J
    PORTERO, JA
    ORFAO, A
    BRITISH JOURNAL OF HAEMATOLOGY, 1992, 80 (03) : 305 - 309